Clinical Trial

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
Trial Details
NCT Number NCT04108208
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms
Enrollment 75 participants
Start Date 2019-12-17
Primary Completion 2023-06-01 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-05